Seth Klarman's Baupost Group sold all its shares in Vaxcyte and Willis Towers Watson during Q2 2026, exiting positions it had only recently established. The move reflects a quick change in risk appetite, especially for Vaxcyte, a clinical-stage biotech with no product revenue and a key vaccine trial data expected in Q4 2026. Baupost's exit suggests the trade was opportunistic rather than a long-term hold. Retail investors should note 13F filings lag by about 45 days, so following such moves without timing awareness can lead to missed exits. Investors interested in Vaxcyte should be prepared to hold through upcoming trial results in late 2026 and early 2027.
Avalanche (AVAX) price fell 2.39% to $6.34 as most altcoins weakened, making AVAX one of the poorest performers despite a flat overall crypto market. The decline lacks a specific catalyst and reflects broad market risk-off sentiment. However, whale a...
Austrian tax law treats swapping Bitcoin for stablecoins as a tax-neutral crypto-to-crypto transaction if the stablecoin qualifies as a cryptocurrency. This means the tax on Bitcoin gains is deferred, not canceled, with acquisition costs transferring...
The S&P 500 showed remarkable earnings growth in Q2 2026, with earnings per share rising 50.8%, largely due to non-operating investment gains and AI-related capital expenditures. Despite a reasonable forward price-to-earnings ratio of 20.7, the marke...
Bitcoin developer Peter Todd proposed a permanent "tail emissions" system to provide miners with a steady stream of new bitcoins after the block subsidy ends around 2140. This idea has sparked strong backlash from the Bitcoin community, which views t...
The tokenized gold market expanded by over $362 million in the past 30 days, driven mainly by Tether Gold (XAUT), which added $237 million to its market cap. XAUT now holds about $2.48 billion in market value, backed by physical gold stored in Swiss ...
